Skip to main content
SpringerLink
Log in

A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson’s disease patients

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Levodopa is the reference treatment for Parkinson’s disease. However, after several years of treatment, dyskinesia may occur and strategies to overcome this side effect still need to be explored. We identified a unique population pharmacokinetic/pharmacodynamic model in Parkinson’s disease to investigate the relationship and dissociability of motor response and dyskinesia.

Methods

Thirty parkinsonian patients (Hoehn and Yahr stages 3–4), treated with levodopa and suffering from peak-dose dyskinesia, were included in a prospective open-label study. They received a single dose of levodopa equal to 150 % of their usual daily dose. Blood samples, motor evaluations (UPDRS III scale) and peak-dose dyskinesia (Goetz scale) were examined after administration. A population pharmacokinetic/pharmacodynamic (PK/PD) model was developed using NONMEM software.

Results

Pharmacokinetic analysis identified a one-compartment model with the following parameter values [bootstrap 95 % CI]: absorption rate constant (KA) 1.86 1/h [1.08–3.25], clearance 36.6 L/h [31.3–42.8], and volume of distribution 42.9 L [34.3–52.3]. Between-subject variability was 122 % [71–183] and 38 % [26–47] for KA and clearance, respectively. Residual variability was 1120 μg/L [886–1290]. UPDRS III and dyskinesia were best described with an effect compartment and similar KE0 values of 1.37 1/h [1.01–1.77]. For UPDRS III, the E0, EC50, Emax, and Hill coefficient were 31.4 [28.4–35.3], 1410 μg/L [1200–1700], 0.72 [0.71–0.75], and 4.26 [3.20–5.58], respectively. For dyskinesia, the EC50 and Emax were 6280 μg/L [3420–37,900] and 17.9 [12.3–80.8], respectively. Residual variability was 3.15 [2.75–3.53] for UPDRS III and 2.66 [1.94–3.51] for dyskinesia. No covariates influenced the parameters.

Conclusions

In patients treated with levodopa and suffering from dyskinesia, the motor response and dyskinesia have close onsets and duration effects. Maximal motor response tends to be inevitably associated with dyskinesia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123:2297–2305

    Article  PubMed  Google Scholar 

  2. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, Hornykiewicz O (2002) Clinical-pathological study of levodopa complications. Mov Disord 17(2):289–296

    Article  PubMed  Google Scholar 

  3. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22(16):2409–2417

    Article  PubMed  Google Scholar 

  4. López IC, Ruiz PJ, Del Pozo SV, Bernardos VS (2010) Motor complications in Parkinson’s disease: ten year follow-up study. Mov Disord 25(16):2735–2739

    Article  PubMed  Google Scholar 

  5. Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol. doi:10.1016/j.pneurobio.2015.07.002.

    PubMed  Google Scholar 

  6. Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190–199

    Article  PubMed  Google Scholar 

  7. Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47(4 Suppl 1):S2–S9 discussion S9-11.

    CAS  PubMed  Google Scholar 

  8. Manson A, Stirpe P, Schrag A (2012) Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis. 2:189–198. doi:10.3233/JPD-2012-120103

    CAS  PubMed  Google Scholar 

  9. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1994) Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson’s disease. Neurology 44:1287–1292

    Article  CAS  PubMed  Google Scholar 

  10. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson’s disease. Ann Neurol 25(5):523–526

    Article  CAS  PubMed  Google Scholar 

  11. Nutt JG, Woodward WR, Carter JH, Gancher ST (1992) Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 49(11):1123–1130

    Article  CAS  PubMed  Google Scholar 

  12. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A (1997) Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study. Clin Neuropharmacol 20:409–418

    Article  CAS  PubMed  Google Scholar 

  13. Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, Ahlskog JE, Dorflinger EE (1994) Utility of an objective dyskinesia rating scale for Parkinson’s disease: inter- and intra-rater reliability assessment. Mov Disord 9:390–394

    Article  CAS  PubMed  Google Scholar 

  14. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912

    Article  CAS  PubMed  Google Scholar 

  15. Wikberg T (1991) Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 9:167–176

    Article  CAS  PubMed  Google Scholar 

  16. Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user’s guides (1989–2009). Icon Development Solutions, Ellicott City, MD

    Google Scholar 

  17. Karlsson MO, Jonsson EN, Wiltse CG, et al. (1998) Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 26:207–246

    Article  CAS  PubMed  Google Scholar 

  18. Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e38. doi:10.1038/psp.2013.14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Brendel K, Comets E, Laffont C, et al. (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036–2049

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods. J Pharmacokinet Pharmacodyn 30:405–416

    Article  CAS  PubMed  Google Scholar 

  21. Holford N, Heo Y-A, Anderson B (2013) A pharmacokinetic standard for babies and adults. J Pharm Sci 102:2941–2952

    Article  CAS  PubMed  Google Scholar 

  22. Jorga K, Banken L, Fotteler B, et al. (2000) Population pharmacokinetics of levodopa in patients with Parkinson’s disease treated with tolcapone. Clin Pharmacol Ther 67:610–620

    Article  CAS  PubMed  Google Scholar 

  23. Troconiz I, Naukkarinen T, Ruottinen H, et al. (1998) Population pharmacodynamic modeling of levodopa in patients with Parkinson’s disease receiving entacapone. Clin Pharmacol Ther 64:106–116

    Article  CAS  PubMed  Google Scholar 

  24. Dietz M et al. (2001) Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson’s disease. Clin Pharmacol Ther 70:33–41

    Article  CAS  PubMed  Google Scholar 

  25. Nutt JG, Holford N (1996) The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann Neurol 39:561–573

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Pharmacologie Clinique, AP-HM, Hôpital Sainte Marguerite, CAP-TV, 13274, Marseille, France

    N. Simon & A. Boulamery

  2. Aix-Marseille Université, INSERM UMR_S 912 (SESSTIM), IRD, 13385, Marseille, France

    N. Simon

  3. Service de neurologie, Centre Hospitalier Intercommunal Aix Pertuis, 13613, Aix-en-Provence, France

    F. Viallet & D. Gayraud

  4. Laboratoire Parole et langage, Aix-Marseille Université, UMR CNRS 7309, 13003, Marseille, France

    F. Viallet

  5. Service de Neurologie, CHU Timone, Marseille, France

    A. Eusebio & J-P. Azulay

Authors
  1. N. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Viallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Boulamery
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Eusebio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Gayraud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J-P. Azulay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Simon.

Electronic supplementary material

ESM 1

(DOCX 87 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simon, N., Viallet, F., Boulamery, A. et al. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson’s disease patients. Eur J Clin Pharmacol 72, 423–430 (2016). https://doi.org/10.1007/s00228-016-2034-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-016-2034-0

Keywords

Search

Navigation